As the field continues to unravel the roles of FOXO3a and USP18 in IPF, it is imperative to move forward with in vivo studies and clinical trials to evaluate the safety, efficacy, and feasibility of these potential therapeutic strategies. The gene discussed is FOXO3; the disease is idiopathic pulmonary fibrosis.